Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04481685
Recruitment Status : Recruiting
First Posted : July 22, 2020
Last Update Posted : August 21, 2020
Sponsor:
Information provided by (Responsible Party):
University of Kansas Medical Center

Brief Summary:

COVID-19 morbidity and mortality has been associated with Cytokine Release Syndrome (CRS) and Acute Respiratory Distress Syndrome (ARDS).

ATI-450 is an oral small molecule MAPKAPK2 (MK2) inhibitor that potently inhibits multiple inflammatory cytokines.

The investigator hypothesizes that MK2 pathway blockade during active COVID-19 infection in hospitalized participants will result in improvement in respiratory-failure free survival.


Condition or disease Intervention/treatment Phase
Covid19 Drug: ATI-450 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Controlled Trial of ATI-450 in Patients With Moderate-severe COVID-19
Actual Study Start Date : July 20, 2020
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2022

Arm Intervention/treatment
Active Comparator: ATI-450
Treated with 50 mg dose of ATI-450, orally, twice daily for 14 days
Drug: ATI-450
50 mg (as determined from Phase I study) per dose. (100 mg per day). Up to a maximum of 14 days while inpatient. Patients discharged home or transferred to the intensive care unit (ICU) will be discontinued off drug permanently.

Placebo Comparator: Placebo
Treated with matched placebo, orally, twice daily for 14 days
Drug: Placebo
Placebo pill will be taken twice daily preferably spaced 12 hours apart.




Primary Outcome Measures :
  1. Respiratory failure-free survival in participants with moderate-severe COVID-19 who are treated with ATI-450 [ Time Frame: Study day 14 ]
    Participants medical record


Secondary Outcome Measures :
  1. Change in 7 point-ordinal scale [ Time Frame: Baseline, Day 7, Day 14, Day 28 and follow-up up to 9 months ]

    Using World Health Organization (WHO) COVID-19 Ordinal scale measuring: Proportion and time to participants with greater than 2 point improvement on the 7 point categorical scale. This scale measures illness severity over time and has a range of 0-7.

    • 0- Uninfected: No clinical or virological evidence of infection.
    • 1- Ambulatory: No limitation of activities.
    • 2- Ambulatory: Limitation of activities.
    • 3- Hospitalized, mild disease: Hospitalized, no oxygen.
    • 4- Hospitalized, mild disease: Oxygen by mask or nasal prongs.
    • 5- Hospitalized, severe disease: Non- invasive ventilation or high- flow oxygen.
    • 6- Hospitalized, severe disease: Intubation and mechanical ventilation.
    • 7- Hospitalized, severe disease: Ventilation + organ support; pressors, Renal Replacement Therapy (RRT), Extracorporeal Membrane Oxygenation (ECMO).

  2. Change in oxygen saturation-normalization [ Time Frame: Baseline and continuous throughout hospitalization up to 14 days ]
    Peripheral capillary pulse oximeter to measure: Oxygen Saturation (SpO2)/Fraction of Inspired Oxygen (FiO2) ratio over time, sustainment of normalization in 24 hours, and relative shifts in SpO2/FiO2 categories (<235, between 235 and 315, greater than 315) over time

  3. Need for advanced respiratory care [ Time Frame: Baseline and continuous throughout hospitalization up to 14 days ]
    Derived from medical record

  4. All-cause mortality [ Time Frame: Baseline and through day 60 ]
    Noted in participant medical record

  5. Percentage of adverse events (AEs) [ Time Frame: Baseline through day 14 or at discharge <day 14, at day 28, day 45 and day 60 ]
    CTCAE v5.0

  6. Percentage of serious adverse events (SAEs) [ Time Frame: Baseline through day 14 or at discharge <day 14, at day 28, day 45 and day 60 ]
    CTCAE v5.0

  7. Proportion of participants with normalization of fever for 24 hours [ Time Frame: Baseline through day 14 or at discharge <day 14 ]
    Standard daily temperature measurement and obtained from participant medical record

  8. Number of participants who develop new bacterial infection [ Time Frame: Continuous throughout hospitalization up to 14 days ]
    Noted in participant medical record

  9. Number of participants who develop new fungal infection [ Time Frame: Continuous throughout hospitalization up to 14 days ]
    Noted in participant medical record

  10. Incidence of Adult Respiratory distress Syndrome (ARDS2) [ Time Frame: From day 1 though day 14 or at discharge <day 14 ]
    Noted in participant medical record

  11. Change in serum cytokine Interleukin (IL)-6 [ Time Frame: Baseline, day 3, day 7 (or discharge <day 7), day 14 (or discharge >day 7 and <day 14) ]
    Serum collected from blood and assayed on Luminex panel performed by University of Kansas Medical Center (KUMC) Biobanking and Biomarker Validation (BBV) Core

  12. Change in serum cytokine IL-8 [ Time Frame: Baseline, day 3, day 7 (or discharge <day 7), day 14 (or discharge >day 7 and <day 14) ]
    Serum collected from blood and assayed on Luminex panel performed by KUMC BBV Core

  13. Change in serum cytokines IL-1β [ Time Frame: Baseline, day 3, day 7 (or discharge <day 7), day 14 (or discharge >day 7 and <day 14) ]
    Serum collected from blood and assayed on Luminex panel performed by KUMC BBV Core

  14. Change in serum cytokine Tumor Necrosis Factor (TNF-α) [ Time Frame: Baseline, day 3, day 7 (or discharge <day 7), day 14 (or discharge >day 7 and <day 14) ]
    Serum collected from blood and assayed on Luminex panel performed by KUMC BBV Core



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Able to comprehend and be willing to sign the Institutional Review Board (IRB)-approved subject informed consent form (ICF) prior to administration of any study-related procedures, or consent from surrogate decision maker when the above criteria cannot be met
  • Male or non-pregnant female adult ≥18 years of age at time of enrollment; female patients must have a negative serum pregnancy test at study enrollment
  • Has laboratory-confirmed COVID-19 coronavirus infection as determined by polymerase chain reaction (PCR), or other commercial or public health assay in oropharyngeal or nasopharyngeal testing within 14 days of hospitalization. An additional 24-hour COVID-19 PCR test will be performed at KUMC. Patients outside of KUMC will have their samples sent to KUMC as a Central Lab for test processing
  • Hospitalized as a result of symptoms and signs related to COVID-19 infection, and ≤14 days since positive test
  • Evidence of hypoxic respiratory failure: SpO2≤93% on room air, or SpO2 >93% requiring ≥ 2 Liters (L) O2, or Pa02/Fi02 ratio <300 Millimeter of Mercury (mmHg), or tachypnea (respiratory rate > 30 breaths/min)
  • Evidence of pulmonary involvement by: chest imaging or pulmonary exam
  • Previous use of hydroxychloroquine or chloroquine is allowed in this study
  • Adequate organ function per laboratory tests
  • Females of child-bearing potential and males with partners of child-bearing potential must agree to practice sexual abstinence or to use the forms of contraception listed in Child-Bearing Potential/Pregnancy section for the duration of study participation and for 30 Days for females and 90 days for males following completion of therapy

Exclusion Criteria:

  • Known hypersensitivity to ATI-450
  • History or evidence of active or latent tuberculosis or recent exposure (within last 30d) to a person with active Tb
  • Evidence of active, untreated bacterial infection. Patients who are treated with antibiotics for at least 72 hours, will become eligible for rescreening for trial enrollment
  • Active use of immunosuppressant medication(s) (i.e. anti-rejection ,immunomodulators or immunosuppressant drugs, including but not limited to IL-6 inhibitors, TNF inhibitors, anti-IL-1 agents and Janus kinase (JAK) inhibitors within 5 half-lives or 30 days (whichever is longer) prior to randomization. (Use of hydroxychloroquine/chloroquine should be discontinued)
  • Oncology patients who are on active chemotherapy or immunotherapy. However, oncology patients who come off active therapy prior to enrollment and have absolute neutrophil count (ANC) ≥1500/mmc are eligible for enrollment
  • Active participation in a concurrent COVID-19 clinical trial with investigative medical drug therapies. However, co-enrollment for non-investigative drug therapies will be allowed; use or re-purposing of FDA approved treatments will be considered at the discretion of the medical monitor
  • In the opinion of the investigator, unlikely to survive for at least 48 hours from screening or anticipate mechanical ventilation within 48 hours
  • Pregnancy or breast feeding
  • Prisoner
  • Intubation and ventilation at time of enrollment
  • Known history for HIV, hepatitis B or C infection. Patients with serologic evidence of hepatitis B vaccination (hepatitis B surface antibody without the presence of hepatitis B surface antigen) will be allowed to participate
  • History of a past or current medical condition that in the opinion of the treating physician would compromise patient safety (e.g. uncontrolled HIV) by participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04481685


Contacts
Layout table for location contacts
Contact: Kimberly Lovell 913-588-6067 klovell@kumc.edu

Locations
Layout table for location information
United States, Kansas
The University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: KUCC Navigation    913-588-3671    kucc_Navigation@kumc.edu   
Sponsors and Collaborators
University of Kansas Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Gregory Gan, MD, PhD The University of Kansas
Principal Investigator: Deepika Polineni, MD, PhD The University of Kansas
Layout table for additonal information
Responsible Party: University of Kansas Medical Center
ClinicalTrials.gov Identifier: NCT04481685    
Other Study ID Numbers: IIT-2020-ATI-450-COVID-19
First Posted: July 22, 2020    Key Record Dates
Last Update Posted: August 21, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No